It had posted a profit of Rs 70.33 crore for the similar period of the previous fiscal, Alembic Pharmaceuticals said in a BSE filing.
The company's consolidated total income from operations rose 24.57 per cent to Rs 626.57 crore for the quarter under review as against Rs 502.98 crore a year ago.
For the full fiscal, the consolidated profit increased by 154.28 per cent to Rs 719.44 crore as against Rs 282.93 crore in 2014-15.
Consolidated total income grew 53.13 per cent to Rs 3,148.71 crore in 2015-16 fiscal as against Rs 2,056.12 crore.
In a separate filing, the company said the board has recommended a dividend of Rs 4 per equity share.
Besides, the board has appointed Chirayu Amin as the Executive Chairman and Chief Executive Officer of the company, with effect from today. It has also appointed Pranav Amin and Shaunak Amin as managing directors.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
